托米沃塞蒂布降低了根基病变患者背部根结节神经元的子宫外活动
Yan Li1, Megan L Uhelski1, Robert Y North2
1Department of Anesthesia and Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Brain : a journal of neurology
|July 24, 2024
概括
托米沃塞蒂布 (Tomivosertib) 是一种基因激活蛋白激酶相互作用激酶 (MNK) 的抑制剂,可逆地抑制了人类感觉神经元中的自发活动. 这一发现为治疗神经病痛提供了一个有希望的途径.
科学领域:
- 神经科学是一个神经科学.
- 疼痛研究 疼痛研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 背脊根结节神经元 (DRG) 的自发活动驱动神经病痛.
- 驱动自发活动的细胞内信号机制尚未在人类恶性感受器上进行测试.
研究的目的:
- 研究MNK抑制对人类感官神经元自发活动的影响.
- 探索tomivosertib作为治疗神经病痛的潜力.
主要方法:
- 使用来自胸椎切除手术的培养人类DRG神经元.
- 电生理学记录评估了神经元活动和行动潜力的特征.
- 西方涂抹或类似的技术测量了eIF4E酸化.
主要成果:
- 托米沃塞蒂布 (25nM) 可逆地抑制了人类感官神经元中的自发活动.
- 治疗降低了作用电位的振幅,并改变了超极化后的电流,这表明对离子通道的影响.
- eFT508治疗迅速降低了eIF4E血清209酸化,一种特定的MNK基质.
结论:
- 抑制MNK有效地抑制了人类恶性受体中的自发活动.
- 托米沃塞蒂布显示出作为治疗神经病痛的治疗剂的潜力.
- 对神经性疼痛的MNK抑制剂进行进一步的临床试验是有必要的.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
279
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
279
Antiepileptic Drugs: Potassium Channel Activators
158
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
158
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
813
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
813
Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156


